3-Dose Pfizer COVID Vaccine Spurs Strong Response in Youngest Kids
MONDAY, May 23, 2022 (HealthDay News) — Pfizer/BioNTech says a three-dose regimen of its COVID-19 vaccine appears to provoke a strong immune response in the youngest age group of children — those aged 6 months to 5 years. This is the only age group not yet approved for COVID-19 vaccinationContinue Reading